Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1996 2
1998 1
1999 2
2000 2
2001 1
2004 3
2005 4
2007 2
2008 2
2009 2
2010 1
2011 2
2012 3
2013 6
2014 2
2015 3
2016 5
2017 5
2018 7
2019 11
2020 9
2021 7
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, Bezzio C, Bar-Gil Shitrit A, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsúr P, Bossuyt P, Schulberg J, Hoentjen F, Viganò C, Palermo A, Torres J, Revés J, Karmiris K, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Calviño Suárez C, Weisshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Surís G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H, Broytman Y, Amir Barak H, Avni-Biron I, Ollech JE, Dotan I, Aharoni Golan M. Yanai H, et al. Among authors: naftali t. J Crohns Colitis. 2022 Dec 5;16(12):1882-1892. doi: 10.1093/ecco-jcc/jjac100. J Crohns Colitis. 2022. PMID: 35895074
Reply.
Naftali T, Reshef L, Kovacs A, Porat R, Amir I, Konikoff FM, Gophna U. Naftali T, et al. Inflamm Bowel Dis. 2016 May;22(5):E15-6. doi: 10.1097/MIB.0000000000000782. Inflamm Bowel Dis. 2016. PMID: 27096566 No abstract available.
Upadacitinib for Acute Severe Ulcerative Colitis.
Zinger CH, Ringel Y, Eitan M, Openhaim M, Kayless H, Stein A, Rudnicki Y, Naftali T. Zinger CH, et al. Among authors: naftali t. Inflamm Bowel Dis. 2023 Oct 3;29(10):1667-1669. doi: 10.1093/ibd/izad180. Inflamm Bowel Dis. 2023. PMID: 37611085 No abstract available.
[MEDICAL CANNABIS].
Naftali T. Naftali T. Harefuah. 2016 Feb;155(2):79-82, 133. Harefuah. 2016. PMID: 27215115 Hebrew.
Cannabis for inflammatory bowel disease.
Naftali T, Mechulam R, Lev LB, Konikoff FM. Naftali T, et al. Dig Dis. 2014;32(4):468-74. doi: 10.1159/000358155. Epub 2014 Jun 23. Dig Dis. 2014. PMID: 24969296 Review.
84 results